Skip to content Skip to footer
Subscribe Now
NEWS

TrueLab Inks ~$985M Deal with Bionyra to Advance Two Immune-Mediated Inflammatory Disease Therapies

Shots: TrueLab has granted Bionyra exclusive worldwide rights, excl. Greater China, to research, develop, manufacture, & commercialize TL-001, an anti-TL1A monoclonal antibody, & TL-003, a TL1A × IL-23p19 bispecific antibody As per the deal, TrueLab will receive ~$985M in total consideration, incl. an upfront payment as well as development, regulatory, & commercial milestone payments, with tiered…
June 23, 2026

Read more

NEWS

Murj Expands Commercial Operations Across Australia and New Zealand for Cardiac Device Management Solutions

Shots: Murj announced the commercial launch of its cardiac device management platform in Australia and expanded availability in New Zealand, following its participation at the CSANZ/HRS Advances in Pacing and Conduction System Pacing Summit in Melbourne The expansion enables healthcare providers across the region to access Murj’s cloud-native solutions for cardiac implantable electronic device (CIED)…
June 22, 2026

Read more

NEWS

Takeda Partners with Boltz to Advance AI-Driven Drug Discovery

Shots: Boltz has partnered with Takeda to deploy its biomolecular AI platform across Takeda’s research organization, providing discovery teams access to proprietary foundation models, incl. BoltzMol-1 & BoltzProt-1, to accelerate AI-driven drug discovery The platform is designed to support in-silico molecular design, enabling structure prediction, affinity estimation, and generative design to enhance AI-driven drug discovery…
June 19, 2026

Read more

NEWS

Voro Therapeutics and Alloy Therapeutics Partner on Next-Generation T-Cell Engagers

Shots: Voro Therapeutics & Alloy Therapeutics have entered into a strategic research collaboration to discover and develop next-generation masked T-cell engager (TCE) therapies Partnership will combine Voro’s PrimeBody platform with Alloy’s optimized CD3 antibodies & multispecific engineering capabilities to develop novel immunotherapies designed to selectively activate immune responses within tumors PrimeBody is designed to unlock difficult-to-target…
June 19, 2026

Read more

NEWS

LabGenius Therapeutics and LG Chem Collaborate to Develop an AI/ML-Designed Tumour-Targeting Antibody

Shots: LabGenius has entered into a multi-year research collaboration, option & licensing agreement with LG Chem to identify next-generation multispecific antibodies for difficult-to-treat cancers, leveraging LabGenius’ AI/ML-driven antibody discovery platform, EVA As per the licensing deal, LabGenius will lead preclinical research, incl. in vitro efficacy studies, after which LG Chem will conduct further preclinical development, incl.…
June 18, 2026

Read more

NEWS

Biogen to Acquire RayThera for ~$1B

Shots: Biogen has entered into a definitive agreement to acquire RayThera, expanding its immunology pipeline As per the deal, Biogen will acquire RayThera for ~$1B, incl. an upfront payment & clinical and regulatory milestone payments; closing is expected in Q3’26 Following closing, Biogen will lead development, manufacturing & global commercialization of RayThera’s assets, incl. the…
June 18, 2026

Read more

NEWS

Jazz Pharmaceuticals and AbCellera Collaborate to Discover T-cell Engaging Multispecific Antibodies

Shots: Jazz has entered into a preclinical research collaboration, option & license agreement with AbCellera to discover & develop next-generation T-cell engaging (TCE) multispecific antibodies for GI cancer & other solid tumors, leveraging AbCellera’s antibody discovery engine  AbCellera will lead discovery & early-stage research for 2 initial programs, with a third to start within…
June 17, 2026

Read more

NEWS

Protillion Biosciences and Merck Enter ~$510M Drug Discovery Collaboration

Shots: Protillion has entered into a multi-target discovery collaboration & license agreement with Merck, integrating Protillion’s Prot-MaP technology with Merck’s global expertise in the discovery of novel therapeutic candidates As per the deal, Protillion will receive an undisclosed upfront payment & ~$510M in research, development, & commercial milestone payments for the successful development of multiple…
June 17, 2026

Read more

NEWS

Dimerix Inks a ~$340M Deal with Everest Medicine to Commercialize DMX-200 in Greater China, South Korea, and Southeast Asia

Shots: Dimerix has granted Everest exclusive rights to commercialize DMX-200 for all indications incl. FSGS, in Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam & Philippines; Dimerix will retain rights outside the licensed regions Dimerix will continue funding & conducting the P-III (ACTION3) study, while Everest will manage regulatory filings, maintenance of the regulatory…
June 16, 2026

Read more

NEWS

XtalPi Secures Over $400M Partnership to Develop GPCR-Targeted Small Molecule Therapy

Shots: XtalPi has entered into a strategic partnership with a biopharmaceutical company to develop an oral small molecule against G protein-coupled receptor XtalPi will leverage its structure-based drug design platform, combining quantum physics, generative AI, large-scale automated chemical synthesis orchestrated by a multi-agent system to accelerate Design-Make-Test-Analyze (DMTA) cycles As per the deal, XtalPi will receive…
June 11, 2026

Read more

Load more